Savastano S, Cannavale V, Valentino R, Tommaselli A P, Rossi R, Luciano A, Tauchmanovà L, Mariano A, Mazzitelli L, Macchia V, Lombardi G
Cattedra di Endocrinologia, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Napoli, Italy.
J Endocrinol Invest. 1999 Nov;22(10):766-71. doi: 10.1007/BF03343642.
The pituitary-thyroid axis and neurohumoral activation indexes were simultaneously investigated in 16 in-patients hospitalized for cardiac heart failure (CHF), New York Heart Association (NYHA), class II-IV, and Killip clinical scale, class II-III, to evaluate their relationship with CHF morbidity and the relative prognostic value. At entry the patients were divided into two subgroups (A and B), according to the severity of CHF. Patients were further classified into two subgroups, according to the subsequent clinical course (C, poor outcome and D, improved clinical course). Blood samples were obtained every day for the radioimmunoassay measurement of plasma alpha-atrial natriuretic peptide (alphaANP), arginine vasopressin (AVP), and thyroid hormones, and the results were compared with those of 12 control subjects. At admission, alphaANP and 3,3',5'-triiodothyronine (rT3) values were higher, while 3,3',5-triiodothyronine (T3) to rT3 (T3/rT3) ratio was lower in subgroups A and B than in controls (p<0.001), respectively, and in C than in D (p<0.001), respectively, according to the prognosis. Conversely, no differences in other thyroid indexes, nor a significant correlation between alphaANP and either rT3 or T3/rT3 ratio were present in any of the subgroups. AVP plasma levels in subgroup A were not statistically different from those of controls, whereas they were significantly decreased in subgroups B and C (p<0.05) and D (p<0.001). In conclusion, these results indicate that in CHF the pituitary-thyroid axis is not altered, that alphaANP and T3/rT3 ratio are non-invasive and reliable predictors of severity and prognosis, while AVP might be affected by the different pathological processes leading to CHF or by the concomitant use of drugs.
对16例因心力衰竭(CHF)住院的患者进行了垂体 - 甲状腺轴和神经体液激活指标的同时研究,这些患者纽约心脏协会(NYHA)心功能分级为II - IV级,Killip临床分级为II - III级,以评估它们与CHF发病率的关系及相对预后价值。入院时,根据CHF的严重程度将患者分为两个亚组(A和B)。根据后续临床病程,患者进一步分为两个亚组(C,预后不良和D,临床病程改善)。每天采集血样,通过放射免疫分析法测定血浆α - 心房利钠肽(αANP)、精氨酸加压素(AVP)和甲状腺激素,并将结果与12名对照受试者的结果进行比较。入院时,亚组A和B中的αANP和反三碘甲状腺原氨酸(rT3)值较高,而三碘甲状腺原氨酸(T3)与rT3的比值(T3/rT3)低于对照组(p<0.001),根据预后情况,C组低于D组(p<0.001)。相反,其他甲状腺指标在任何亚组中均无差异,αANP与rT3或T3/rT3比值之间也无显著相关性。亚组A中的AVP血浆水平与对照组无统计学差异,而在亚组B和C中显著降低(p<0.05),在D组中显著降低(p<0.001)。总之,这些结果表明,在CHF中垂体 - 甲状腺轴未改变,αANP和T3/rT3比值是严重程度和预后的非侵入性可靠预测指标,而AVP可能受导致CHF的不同病理过程或同时使用药物的影响。